Has Walaya Methodius-Rayford, MD received payments from drug or device companies?

Yes. Drug and device makers reported $78,921 in general payments to Walaya Methodius-Rayford, MD across 157 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Walaya Methodius-Rayford, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Walaya Methodius-Rayford, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Walaya Methodius-Rayford, MD

Vascular Surgery · Atlanta, GANPI 1407091499

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $61,155 of the $78,921 with a category attached, or 77.5%. 28 manufacturers reported payments, led by Reprise Biomedical, Inc. at 48.7% of the total. Among vascular surgery clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$78,921in general payments, 2019–2025

Across 157 payments — averaging $502.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Reprise Biomedical, Inc.$38K
Progenacare Global, LLC$30K
Angiodynamics, Inc.$4K
Artivion, Inc.$3K
Boston Scientific$1K
Mimedx Group, Inc.$635
plus $1K from 22 others

What the payments were for

Consulting fees$61,15577%
Travel & lodging$7,4589%
Food & beverage$5,9438%
Education$640%
Other$4,3005%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Reprise Biomedical, Inc.	34	$38,459
Progenacare Global, LLC	12	$29,874
Angiodynamics, Inc.	5	$4,351
Artivion, Inc.	2	$3,111
Boston Scientific	62	$1,250
Mimedx Group, Inc.	2	$635
Johnson & Johnson	11	$303
TELA Bio, Inc.	1	$128
Acell, Inc.	2	$123
Medtronic	1	$123
Urgo Medical North America, LLC	1	$73
Melinta Therapeutics, LLC	2	$52
Smith+Nephew	3	$51
Tactile Systems Technology Inc	2	$50
W. L. Gore & Associates, Inc.	2	$46
Integra Lifesciences Corporation	2	$42
Kerecis Limited	1	$34
Surmodics, Inc.	1	$32
Bard Peripheral Vascular, Inc.	2	$29
Abbott	1	$24
Solventum Corporation	1	$22
Cordis US CORP.	1	$21
Lilly USA, LLC	1	$17
Pfizer	1	$15
Osiris Therapeutics Inc.	1	$15
Organogenesis Inc.	1	$15
Reapplix Inc.	1	$14
Silk Road Medical, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,921 in reported general payments places this provider in the 95th percentile of 176 vascular surgery providers in Georgia.

See all vascular surgery providers in Georgia →

Medicare billing

Part B allowed, 2024

$105,083

Medicare patients

Services billed

526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Pentoxifylline	18	$608
ClopidogrelClopidogrel Bisulfate	68	$564
Cilostazol	37	$390
Ibuprofen	24	$143

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Atlanta

Siddharth PatelAtlanta$303K
Andrew UnzeitigAtlanta$46K
Yazan DuwayriAtlanta$44K
Anumeha WhisenhuntAtlanta$33K
James ChangAtlanta$31K
Chad AlemanAtlanta$21K
Olamide AlabiAtlanta$19K
Jorge CorsoAtlanta$18K
Peter H DoublerAtlanta$15K
Eyal Ben-ArieAtlanta$14K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →